Medicare Part B will cover treatments for Alzheimer’s disease that receive U.S. Food and Drug Administration approval, according to the federal agency that administers the program for seniors.
Anyone who has Medicare Part B and meets “eligibility criteria” will be covered for new antibody treatments such as Leqembi once the FDA approves them, said Chiquita Brooks-LaSure, the administrator of the Centers for Medicare & Medicaid Services, on Thursday.
The new policy will provide broader access to treatments, such as Leqembi, that slow cognitive decline.
But patients will have to participate in so-called registries that collect real-world data on how the drugs work.
Brooks-LaSure said the expanded coverage will go into effect on the same day the FDA approves an Alzheimer’s antibody treatment. The FDA is expected to make a decision about Leqembi on July 6.
The drug regulator’s committee of independent advisors is set to meet on June 9 to discuss the data supporting Eisai’s and Biogen’s application for the FDA to fully approve Leqembi.
The FDA granted accelerated approval to Leqembi in January, but Medicare severely restricts coverage for Alzheimer’s antibody treatments that are cleared under that expedited pathway.
As a result, seniors currently cannot access Leqembi unless they are able to personally afford the drug’s $26,500 annual price.
The Alzheimer’s Association, which lobbies for patients living with the disease, for months has called on Medicare to drop restrictions on Leqembi and fully cover the drug.
“We continue to believe that registry as a condition of coverage is an unnecessary barrier,” said Robert Egge, the association’s chief public policy officer.
Brooks-LaSure told Congress in April a registry “in no way limits people getting access to the drug.” She said at the time the goal is to set up the system when the FDA makes its decision on Leqembi on July 6.
CMS will facilitate a nationwide portal in which clinicians can enter the required data, Brooks-LaSure said Thursday.
Her agency is also in talks with multiple organizations planning to set up their own registries, she said.
A study in a leading medical journal recently projected Leqembi could cost Medicare up to $5 billion a year.
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
This article originally appeared here and was republished with permission.
